CD25 Biology Opens Doors to Innovative AML/ALL Treatments

In this interview with Targeted Oncology, Markus Müschen, MD, PhD, Yale School of Medicine, recaps the most significant highlights from his newly published study inquiring into the role of CD25 in high-risk acute leukemias,¹ including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL), and outlines next steps for investigation.

Watch the first part of Dr Müschen’s interview.

Traditionally regarded merely as a surface marker or a prognostic indicator for aggressive leukemia subtypes, CD25 is now recognized as a functional regulator of oncogenic signaling. Müschen explains that CD25 recruits a multiprotein complex that fine-tunes signaling from strong oncogenes, ensuring that signaling is neither too weak nor excessively strong—a “Goldilocks” principle that ultimately promotes leukemia cell growth.

This refined understanding of CD25 biology opens new avenues for therapeutic exploration. The complex that CD25 orchestrates includes multiple druggable proteins, presenting opportunities for additional target discovery that could benefit patients with refractory leukemia. Notably, Müschen emphasizes that the conceptual framework of this approach diverges from conventional targeted therapy strategies. While most therapies aim to inhibit oncogenes, the approach discussed here is designed to leverage toxic hyperactivation of oncogenic pathways. By selectively amplifying oncogene signaling under controlled conditions, it may be possible to identify vulnerabilities that are otherwise hidden in leukemia cells, potentially leading to an entirely novel class of treatments for AML and ALL.

Müschen’s work provides a glimpse into a paradigm shift in leukemia research, where understanding the nuanced regulation of oncogenic signaling by molecules like CD25 could transform how clinicians approach refractory cases. The work not only advances the fundamental biology of leukemia but also suggests innovative strategies for precision-targeted therapies, underscoring the importance of exploring complex regulatory networks rather than single molecular targets.

REFERENCE

1. Lee J, Sun R, Kume K, et al. Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia. Sci Signal. 2026;19(924). doi:10.1126/scisignal.adw5054